Lilly’s Solanezumab Reaches End Of Road As Donanemab Stays On Development Path

The last ongoing clinical trial of Eli Lilly and Company’s anti-amyloid antibody solanezumab has finally concluded and it failed to prevent symptomatic Alzheimer’s disease, but the data did offer some evidence that Lilly’s two remaining Phase III amyloid-clearing antibodies – donanemab and remternetug – may be able to benefit AD patients.

The company reported on 9 March that solanezumab failed to slow cognitive decline and reduce the risk of disease progression in patients with preclinical AD – people with amyloid plaques in their brains but no symptoms of AD – who were enrolled in the Phase III Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4) study